Dong-A ST Launches New Epilepsy Drug 'Xcopri' in South Korea
Developed by SK Biopharmaceuticals
South Korea's 41st domestically developed novel drug
Third-generation treatment with a dual mechanism of action
The epilepsy drug Xcopri (generic name: cenobamate), developed by SK Biopharmaceuticals, is now being prescribed in South Korea. It is expected to offer a new treatment option for patients whose seizures are not adequately controlled by existing medications.
On November 2, Dong-A ST announced the domestic launch of Xcopri tablets, a treatment for epilepsy. Xcopri was approved by the Ministry of Food and Drug Safety in November 2025 as South Korea's 41st domestically developed novel drug. It is used as an adjunctive therapy for adults with focal seizures that are not adequately controlled by existing anti-seizure medications. The drug is now covered by national health insurance, reducing patients' out-of-pocket medication costs.
Epilepsy is a chronic neurological disorder in which abnormal electrical signals in the brain's nerve cells cause recurrent seizures. An estimated 360,000 people in South Korea have epilepsy, and about 30% of them are known to have drug-resistant epilepsy, in which seizures continue despite adequate medication. Seizures are unpredictable and can lead to falls, fractures or burns, while also restricting daily activities such as driving, studying and working.
For this reason, an important goal of epilepsy treatment is not only to reduce the frequency of seizures, but to achieve complete seizure freedom. Xcopri is a third-generation treatment with a dual mechanism of action: it suppresses excessive excitation in brain nerve cells while enhancing inhibitory activity. It is taken once a day, with the dose increased gradually depending on the patient's condition.
Clinical trials have also confirmed its efficacy. In the trial that supported approval by the U.S. Food and Drug Administration (FDA), seizure frequency among 437 adults with focal seizures fell by about 55% in both the 200 mg and 400 mg groups. During the 12-week maintenance period, 11% of patients in the 200 mg group and 21% in the 400 mg group had no seizures, compared with 1% in the placebo group. In an Asian Phase 3 trial involving 519 patients from South Korea, China and Japan, the rates of complete seizure freedom during the six-week maintenance period were 30.1% in the 200 mg group and 52.4% in the 400 mg group, far exceeding the 2.6% in the placebo group.
In January 2024, Dong-A ST signed a licensing agreement with SK Biopharmaceuticals for Xcopri in 30 countries, including South Korea and other Asian markets, Russia, Australia and Türkiye. Dong-A ST is responsible for regulatory approvals and sales in these countries, as well as production of the finished drug.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Dong-A ST representative said, "We hope Xcopri will establish itself as a new treatment option for people with epilepsy. We will contribute to helping patients ease the daily difficulties caused by seizures and continue their treatment with stability."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.